Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations
Johnson & Johnson certainly hasn’t had the easiest COVID-19 shot rollout. Still, with sales predictions ranging in the billions and a series of manufacturing improvements ongoing, the company sees its pandemic hustle as the start of a new era for an emerging vaccine business. Johnson & Johnson is forecasting $ 2.5 billion in full-year sales of its one-shot COVID-19 vaccine, company… Read More »
